Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue. We will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your samples. We will only use extra tissue left over after all needed testing has been done or remove an additional small amount of tissue if you are having a biopsy. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of sarcoma.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma|
- establish and maintain a specimen bank and sarcoma cell line resource [ Time Frame: 2 years ] [ Designated as safety issue: No ]for laboratory-based studies on the causes, prevention, diagnosis and treatment of human soft tissue sarcoma
- identify new rational therapeutic targets [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||June 2002|
|Estimated Study Completion Date:||June 2016|
|Estimated Primary Completion Date:||June 2016 (Final data collection date for primary outcome measure)|
Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
Other: Specimen protocol
The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
In this protocol, we plan to identify specific markers from biochemical, proteomic, epigenetic and molecular genetic analyses that predict clinical outcome, responsiveness to therapy and might serve as promising therapeutic targets in patients with soft tissue sarcoma.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00579566
|Contact: Samuel Singer, M.D.||212-639-2940|
|United States, New York|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|new York, New York, United States, 10065|
|Contact: Samuel Singer, M.D. 212-639-2940|
|Principal Investigator: Samuel Singer, M.D.|
|Principal Investigator:||Singer Singer, M.D.||Memorial Sloan Kettering Cancer Center|